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Abstract
Aims/hypothesis In previous studies, the risk of developing familial type 1 diabetes has been reported to be more than two times
higher in the offspring of affected fathers than in those of affected mothers. We tested the hypothesis that index children with an
affected father may have a more aggressive disease process at diagnosis than those with other affected first-degree relatives.
Methods A cross-sectional, observational study was performed using the Finnish Pediatric Diabetes Register. Clinical and
metabolic characteristics, beta cell autoantibodies and HLA class II genetics were analysed from index children in Finland
diagnosed before the age of 15 years between January 2003 and December 2016. Information on the presence of type 1 diabetes
in first-degree relatives was collected at diagnosis using a structured questionnaire.
Results Out of 4993 newly diagnosed index children, 519 (10.4%) had familial type 1 diabetes. More than 5% (n = 253, 5.1%)
had an affected father, 2.8% (n = 141) had an affected mother, 1.9% (n = 95) had an affected sibling and 0.6% (n = 30) had two or
more affected family members. All clinical and metabolic variables were markedly poorer in children with sporadic vs familial
diabetes. The index children with an affected father or mother were younger than those with an affected sibling (median age 7.59
vs 6.74 vs 10.73 years, respectively; p < 0.001). After age- and sex-adjusted analyses, index children with an affected father
presented more often with ketoacidosis (9.7% vs 3.6%; p = 0.033) and had greater weight loss before diagnosis (3.2% vs 0%;
p = 0.006) than those with an affected mother. Children with familial disease tested negative for all autoantibodies more often
(3.5% vs 2.1%; p = 0.041) and had insulin autoantibodies more frequently (49.8% vs 42.2%; p = 0.004) than those with sporadic
disease. Both major HLA risk haplotypes (DR3-DQ2 and DR4-DQ8) were more often lacking among children with sporadic vs
familial disease (15.9% vs 11.2%; p = 0.006). The DR4-DQ8 haplotype was more frequent in the familial vs the sporadic group
(75.7% vs 68.5%; p = 0.001) and especially among children with an affected father when compared with children with sporadic
disease (77.5% vs 68.5%; p < 0.05). When comparing index children with affected parents diagnosed before or after the birth of
the index child, a clear male preponderance was seen among the affected parents diagnosed before the birth of the index child
(fathers 66.2% vs mothers 33.8%; p = 0.006), whereas the proportion of fathers and mothers was similar if type 1 diabetes was
diagnosed after the birth of the index child.
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Conclusions/interpretation The more severe metabolic derangement at diagnosis in children with sporadic type 1 diabetes
compared with those with familial type 1 diabetes was confirmed. The higher frequency of diabetic ketoacidosis and increased
weight loss at diagnosis in index children with an affected father compared with an affected mother support the hypothesis that
paternal type 1 diabetes is associated with more severe disease in the offspring than maternal diabetes. The sex difference seen
between affected parents diagnosed before and after the birth of the index child supports the hypothesis that maternal insulin
treatment protects against type 1 diabetes.
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Abbreviations
DiMe Childhood Diabetes in Finland
FDR First-degree relative
FPDR Finnish Pediatric Diabetes Register
GADA Antibodies to GAD
IAA Insulin autoantibodies
IA-2A Antibodies to islet antigen 2
ICA Islet cell antibodies
ZnT8A Zinc transporter 8 autoantibodies
Introduction
Warram et al first reported a higher risk of type 1 diabetes in
the children of affected fathers compared with the children of
affected mothers [1], and this has been confirmed in many
other studies [2–9]. However, there are few recent studies,
and methodological differences in study designs make the
comparison of existing studies challenging. Moreover, studies
have focused on the prevalence and incidence rate of familial
type 1 diabetes, as well as on the risk of disease transmission
from parents to offspring or comparisons between parent–
offspring and sib-pair groups. A more severe metabolic de-
rangement at diagnosis has been observed in individuals with
sporadic compared with familial type 1 diabetes [4, 8, 10–13].
However, little is known about possible differences in disease
presentation at diagnosis of type 1 diabetes according to who
in the family is also affected by type 1 diabetes.
Despite the confirmed fact of a stronger disease transmis-
sion to offspring from an affected father compared with an
affected mother, the mechanism behind this phenomenon is
still poorly understood. Both genetic and environmental hy-
potheses have been proposed. These include preferential
transmission of HLA susceptible genes from the father to the
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offspring [14, 15]; genomic imprinting resulting in diabetes-
susceptible gene inactivation in the offspring of affected
mothers but not in those of affected fathers [16]; a tolerogenic
environment in insulin-treated mothers during pregnancy [1,
17]; and the selective loss of fetuses of affected mothers car-
rying susceptibility to type 1 diabetes by spontaneous abortion
[1]. This last hypothesis of higher perinatal mortality rate in
fetuses of affected mothers does not, however, appear to ex-
plain this phenomenon. Warram et al in their later work [18]
found that the risk of type 1 diabetes in the offspring remained
basically the same over several decades, despite a significant
decrease in perinatal mortality rate over the same time period.
The aim of our study was to analyse the impact of the
relationship of the family member affected by type 1 diabetes
on clinical, humoral and genetic characteristics in the index
child at diagnosis of type 1 diabetes. Since the risk of type 1
diabetes is two- to threefold higher among those with an af-
fected father compared with those with an affected mother, we
expected the index children with an affected father to have
signs of a more aggressive disease process than those with
an affected mother or sibling.
Methods
Study design and subjects The Finnish Pediatric Diabetes
Register (FPDR) and Sample Repository has provided clinical
and biochemical information on children newly diagnosed
with diabetes and their families since 2002, and covers more
than 90% of those diagnosed with diabetes in Finland [19].
The coverage of the Sample Repository is approximately 70%
of participants. The newly diagnosed children have been treat-
ed in 23 centres, of which five are university hospitals.
Between January 2003 and December 2016, 6913 children
and adolescents diagnosed with type 1 diabetes under the age
of 15 years were registered in the FPDR. We excluded 1747
children because of a lack of blood samples available for the
analyses of diabetes-associated autoantibodies and HLA
genotyping (Fig. 1). A comparison between the included and
excluded participants has been presented in our previous work
[20]. Only the first diagnosed child per family who fulfilled
the inclusion criteria was included as an index child. Three
children potentially suffering from neonatal diabetes (age at
diagnosis <6 months) and one child later diagnosed with
maturity-onset diabetes of the young were excluded.
Consequently, the study cohort included 4993 children, of
whom 56.6% were boys and the mean age was 8.03 years
(SD 3.89, range 0.52–14.99 years).
Information on the family history of all types of diabetes
was collected from the families using a structured question-
naire. First-degree relatives (FDRs) included the father, the
mother and the full siblings of the affected child. The register
does not provide follow-up data from families after the
diagnosis. In the current analyses, we took into account the
family history of type 1 diabetes in FDRs at the time of diag-
nosis of the index child. The study cohort was categorised into
four familial subgroups based on which family member or
members were affected by type 1 diabetes (father, mother,
sibling or more than one affected FDR) and those with spo-
radic disease. Children with no information on the family
history of type 1 diabetes (n = 57) were counted as having
sporadic disease.
Written informed consent was required from a parent or a
legal caretaker and from participants aged 18 years or older.
Children aged 10–17 years gave informed assent. The study
protocol was approved by the Ethics Committee of the
Hospital District of Helsinki and Uusimaa.
We first compared children with familial and sporadic disease
at the time of clinical diagnosis. A more detailed comparison
between the four familial subgroups and those with sporadic
disease was further performed, and in case of significant differ-
ences, paired comparisons by groups were also performed.
Markers of metabolic decompensation at diagnosis Local lab-
oratories analysed blood pH and the levels of plasma glucose
and β-hydroxybutyrate at diagnosis. Standardised HbA1c
values were available only from those diagnosed after 2012.
The clinician in charge of the initial treatment of the index
child assessed weight loss and level of consciousness at the
time of hospital admission. The duration of classic symptoms
before diagnosis was obtained by interviewing the parents
using a structured questionnaire. Ketoacidosis was defined
as blood pH <7.30 and severe ketoacidosis as blood pH
<7.10 at diagnosis.
Autoantibody assays and HLA genotyping The biochemical
autoantibodies: insulin autoantibodies (IAA), antibodies to
GAD (GADA), islet antigen 2 (IA-2A) and zinc transporter
8 (ZnT8A) were analysed with specific radiobinding assays
described previously [21, 22]. Levels of islet cell antibodies
(ICA) were quantified with indirect immunofluorescence of
pancreatic tissue obtained from a blood group O (0) donor
[23]. Since exogenous insulin treatment may induce insulin
antibodies, we excluded those with serum samples taken later
than 30 days after diagnosis (255 of 4993, 5.1%) for the au-
toantibody analyses.We have previously observed that insulin
antibody levels 1 month after the diagnosis correlate more
strongly with the IAA titers at diagnosis than with insulin
antibody levels 3 months later. Typing of the major HLA
DR-DQ haplotypes was performed with PCR-based lantha-
nide-labelled hybridisation and time-resolved fluorometry de-
tection [24]. Detailed information on the assays is in the elec-
tronic supplementary material (ESM) Methods.
Statistical analysis Statistical analyses were performed using
SPSS software (SPSS Statistics 24; IBM, Chicago, IL, USA)
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and the R 3.4.0 package (https://cran.r-project.org/).
Frequencies in each study group were compared using cross-
tabulation and the χ2 or Fisher’s exact tests. We used
Pearson’s χ2 test for cross-tabulating polytomous variables
with continuity correction when appropriate. Differences in
levels of normally distributed variables were analysed using
Student’s t test. Non-parametric variables were tested using
the Mann–Whitney U test and Kruskal–Wallis test. Adjusted
analyses for confounding factors were performed using logis-
tic/ordinal/multinomial regression for dichotomous/ordinal/
categorical variables and quantile regression in R (package
quantreg) for skewed variables. A p value of 0.05 or less
was considered statistically significant. Bonferroni’s correc-
tion for multiple comparisons was not applied due to its overly
conservative nature. Multiplicity issues were taken into ac-
count in cautious interpretation of the results.
Results
Demographic information At diagnosis, 519/4993 (10.4%)
children had at least one FDR with type 1 diabetes. The
proportion of index children with an affected father was 1.8
and 2.7 times higher compared with those with an affected
mother (p < 0.001) or sibling (p < 0.001) (n = 253 [5.1%] vs
n = 141 [2.8%] and n = 95 [1.9%], respectively). A higher
proportion of index children had an affected mother than an
affected sibling (p < 0.003). Only 30 index children (0.6%)
had two or more affected FDRs with type 1 diabetes (Fig.
1). The number of children in each family and the birth order
of the index child in relation to the presence of an affected
father or mother are presented in the ESM Results section and
ESM Table 1.
Similar age at diagnosis and a similar male:female ratio
was found between childrenwith familial and sporadic disease
(Table 1). A younger age at diagnosis was seen in index chil-
dren with an affected father or mother compared with those
with an affected sibling (median 7.59 and 6.74 years vs
10.73 years, respectively; p < 0.001, Fig. 2). There was a
notable male preponderance (76.7%) among those with two
ormore affected FDRs comparedwith the male:female ratio in
the other groups (p = 0.061, Table 2). In addition, the propor-
tion of boys among the offspring of affected mothers (48.2%)
diverged from that in the whole study population (56.6%),
4993 children
Familial type 1 diabetes 
n=519 (10.4%)
Sporadic type 1 diabetes
n=4474 (89.6%)
Father
n=253 (5.1%)
Mother
n=141 (2.8%)
Two or more 
FDRs
n=30 (0.6%)
Brother
n=56 (1.1%)
Sister
n=39 (0.8%)
Sibling 
n=95 (1.9%)
Three FDRs 
n=1
Four FDRs
n=1
Two FDRs
n=28
6913 childrenExcluded:
• 1747 with no blood samples
• 169 later-diagnosed siblings
• 3 with neonatal diabetes
• 1 later diagnosed with MODY
Both parents
n=6
Two siblings
n=8
Parent and sibling
n=14
Father and 
two siblings
Both parents 
and two 
siblings
Fig. 1 Flow diagram showing
inclusion and exclusion criteria
and grouping of the index
children according to the
relationship to the affected FDR.
All children and adolescents were
diagnosed between 2003 and
2016, with age at diagnosis
≤15 years
Table 1 Demographic, metabolic, immunological and genetic markers in children with familial and sporadic type 1 diabetes
Variable n Familial, n=519 (10.4%) Sporadic, n=4474 (89.6%) p value Adjusted p valuea
Demographics
Age at diagnosis, years, mean ± SD 4993 7.84 ± 3.88 8.05 ± 3.89 0.229
Sex, male, % (95% CI) 4993 55.7 (51.4, 60.0) 56.7 (55.2, 58.1) 0.705
Pubertal, % (95% CI) 3764 16.9 (13.2, 20.6) 17.2 (15.9, 18.4) 0.941 0.445
Metabolic decompensation at diagnosis
Duration of symptoms, % 4614 <0.001 <0.001
No symptoms 2.1 0.8
< 1 week 38.1 20.8
1–4 weeks 46.6 58.7
> 4 weeks 13.1 19.7
Impaired consciousness, % (95% CI) 4784 1.6 (0.5, 2.7) 5.9 (5.2, 6.6) <0.001 <0.001
Ketoacidosis, % (95% CI) 4817 7.8 (5.4, 10.1) 19.1 (18.0, 20.3) <0.001 <0.001
Severe ketoacidosis, % (95% CI) 4817 2.4 (1.1, 3.7) 4.9 (4.2, 5.5) 0.017 0.018
Weight loss, %, median (range) 4610 2.0 (0–25.3) 5.6 (0–40.0) <0.001 <0.001
pH, median (range) 4817 7.40 (6.93–7.57) 7.38 (6.72–7.54) <0.001 <0.001
β-Hydroxybutyrate, mmol/l, median (range) 4384 0.50 (0–18.0) 1.90 (0–27.0) <0.001 <0.001
Plasma glucose, mmol/l, median (range) 4869 20.8 (3.6–63.7) 24.2 (3.2–97.6) <0.001 <0.001
HbA1c, mmol/mol, median (range) 841 76.0 (38.0–141.5) 92.0 (36.0–189.0) <0.001 <0.001
HbA1c, %, median (range) 841 9.1 (5.6–15.1) 10.6 (5.4–19.4) <0.001 <0.001
Autoantibodies
ICA, % (95% CI) 4738 90.9 (88.3, 93.5) 91.8 (91.0, 92.7) 0.535 0.400
ICA, JDFU, median (range) 4347 64.0 (3.0–2620.0) 64.0 (3.0–5120.0) 0.894 0.585
IAA, % (95% CI) 4738 49.8 (45.3, 54.2) 42.2 (40.7, 43.7) 0.002 0.004
IAA, RU, median (range) 2037 10.5 (2.9–484.9) 10.2 (2.8–7809.0) 0.771 0.329
IA-2A, % (95% CI) 4738 75.4 (71.6, 79.2) 75.0 (73.7, 76.3) 0.890 0.806
IA-2A, RU, median (range) 3556 104.2 (0.8–223.2) 105.8 (0.8–553.3) 0.768 0.811
GADA, % (95% CI) 4738 67.1 (63.0, 71.3) 66.3 (64.8, 67.7) 0.735 0.679
GADA, RU, median (range) 3144 43.3 (5.4–3800.0) 35.7 (5.4–24,849.0) 0.245 0.080
ZnT8A, % (95% CI) 4738 66.3 (62.1, 70.5) 69.8 (68.4, 71.1) 0.132 0.155
ZnT8A, RU, median (range) 3289 12.0 (0.5–186.7) 12.1 (0.5–1201.9) 0.753 0.767
Number of positive antibodies, median (mean) 4738 4 (3.50) 4 (3.45) 0.252 0.183
Number of positive biochemical antibodies, median (mean) 4738 3 (2.59) 3 (2.53) 0.182 0.211
Autoantibody negative, % (95% CI) 4738 3.5 (1.9, 5.2) 2.1 (1.7, 2.6) 0.079 0.041
Positivity for multiple (≥2) autoantibodies, % (95% CI) 4738 92.8 (90.5, 95.1) 92.5 (91.7, 93.2) 0.875 0.911
Genetics 4993
DR3-DQ2/DR4-DQ8, % (95% CI) 23.7 (20.0, 27.4) 21.1 (19.9, 22.2) 0.182 0.186
DR3-DQ2/xb, % (95% CI) 13.1 (10.2, 16.0) 15.6 (14.5, 16.6) 0.156 0.143
DR4-DQ8/yc, % (95% CI) 52.0 (47.7, 56.3) 47.5 (46.0, 48.9) 0.055 0.049
xb/yc, % (95% CI) 11.2 (8.5, 13.9) 15.9 (14.8, 17.0) 0.006 0.006
DR3-DQ2, % (95% CI) 36.8 (32.7, 41.0) 36.6 (35.2, 38.0) 0.979 0.975
DR4-DQ8, % (95% CI) 75.7 (72.0, 79.4) 68.5 (67.1, 69.9) 0.001 0.001
Risk group, % 0.157 0.162
0 0.4 0.8
1 1.7 2.1
2 13.5 16.2
3 20.4 23.0
4 40.3 36.8
5 23.7 21.1
Categorical variables are presented as % (95% CI) and continuous variables as mean (SD) or median (range)
For comparing frequencies, cross tabulation and χ2 statistics with continuity correction or Fisher’s exact test when appropriate were used. Differences in
levels of parametric variables were analysed with Student’s t test, and Kruskal–Wallis test or Mann–Whitney U test for non-parametric variables
Adjustment for confounding factors was performed using logistic/ordinal/multinomial regression for dichotomous/ordinal/categorical variables and
quantile regression in R for skewed variables
a Adjusted for sex and age at diagnosis
b x ≠ DR4-DQ8
c y ≠ DR3-DQ2
JDFU, Juvenile Diabetes Foundation units; RU, relative units
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while the proportion of boys was similar (56–57%) in the
other familial subgroups. Both sexes had a father with type 1
diabetes (5.1% of boys vs 5.0% of girls; p = 0.80) and a sibling
with type 1 diabetes (1.9% for both sexes; p = 0.88) equally
often. However, the proportion of girls with an affected moth-
er was significantly higher than that of boys (3.4% vs 2.4%;
2030 Diabetologia (2019) 62:2025–2039
p = 0.04) (see ESM Results). The proportion of children with
two or more affected FDRs was 0.8% among boys and 0.3%
among girls (p = 0.03).
Metabolic decompensation at diagnosis After age- and sex-
adjusted analyses, children with sporadic disease had poorer
values for all clinical and metabolic variables than children
with familial disease (Table 1). Index children with an affected
father had a longer duration of classic symptoms compared
with other familial subgroups (Table 2). They also presented
more often with ketoacidosis (9.7% vs 3.6%; p = 0.033, Fig.
3) and had greater weight loss before diagnosis, compared
with those with an affected mother (Table 2). The measured
laboratory values at diagnosis were similar in the different
familial subgroups.
Autoantibodies When adjusted for age and sex, autoantibody
negativity was more frequent among children with familial vs
sporadic disease (Table 1), and a similar difference was seen
especially among those with more than one affected FDR
compared with those with sporadic disease, although it did
not reach statistical significance after adjustment (p = 0.091)
(Table 3). The frequency of IAA was higher in the familial
group, but all other autoantibody frequencies and titres were
similar in familial compared with sporadic groups, and no
differences were detected in the number of positive autoanti-
bodies (Table 1).
HLA genetics After adjusting for age and sex, the risk haplotype
DR4-DQ8 was more common in the familial vs sporadic group
(Table 1), and a higher prevalence of DR4-DQ8 heterozygosity
as well as DR4-DQ8 homozygosity was observed in those with
an affected father vs those with sporadic disease, in particular
(Table 4). The genotypes missing both major risk haplotypes
(DR3-DQ2 and DR4-DQ8) were more common in the sporadic
group compared with the familial group (Table 1). There was no
difference in the proportions of genetic risk groups between chil-
dren with familial or sporadic disease, or between different fa-
milial subgroups (Tables 1 and 4).
Timing of diagnosis in the affected parent in relation to dis-
ease characteristics in the index childWe compared offspring
with parents diagnosed with type 1 diabetes before and after
the birth of the index child (Table 5). In these analyses, we
included all the index children known to have affected parents,
and also those classified into the group of two or more affected
FDRs in previous analyses. If both parents of an index child
had type 1 diabetes (six children) then we took into account
only the information from the affected mothers. Thus, in 349
cases (87%) the parent was diagnosed before the birth of the
index child, and in 52 cases (13%) the parent was diagnosed
after the birth of the index child.
There were no significant differences in the sex distribution
of the index children between the groups. In contrast, a clear
predominance of affected men was seen among the affected
parents diagnosed before the birth of the index child (66%),
whereas the proportion of affected fathers and mothers was
similar when their type 1 diabetes was diagnosed after the
birth of the index child. Index children were younger if the
parent was diagnosed before vs after the birth of the index
child. A similar difference was seen in subanalyses of index
children with an affected mother (median age 5.57 vs
9.77 years, p < 0.001), but not in subanalyses of index chil-
dren with an affected father (data not shown). After adjusting
for age and sex, median HbA1c values at diagnosis of type 1
diabetes were higher in those children whose parents were
diagnosed after the birth of the index child, whereas no other
significant differences were observed in the metabolic charac-
teristics or in the risk profile of HLA genetics between the two
groups. Apart from higher IA-2A frequencies in children with
affected parents diagnosed after the birth of the index child, no
other differences were found between the groups in the auto-
antibody profile.
Discussion
In this cross-sectional nationwide study, a positive family his-
tory of type 1 diabetes was observed in 10.4% of participating
children at the time of diagnosis. This frequency is in line with
previous reports, in which the proportion has varied between 9
and 12% [4, 6, 9, 12, 13, 25–27]. As expected, the number of
children with an affected father was about twofold higher than
that of children with an affected mother [2, 5, 7, 8, 26]. The
proportion of index children with an affected sibling (1.9%)
was lower than previously observed in Finnish and Danish
studies ( 5%) [4, 6, 13]. This may be due to the fact that
siblings diagnosed after the index child were not considered
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in the current study. The proportion of those with an affected
sibling was based on all index children, irrespective of the
number of known siblings. Moreover, index children with
two or more affected FDRs, at least one being a sibling, were
categorised into the group of multiple affected family mem-
bers and not included in the group of affected siblings. In the
Childhood Diabetes in Finland (DiMe) study, the
categorisation was similar to that used in the current study
and the proportion of index children with a sibling with type
1 diabetes (2.6%) was closer to our finding [28]. We cannot
disregard the potential effect of a decreasing birth rate and
reduced family size seen in Finland on the number of siblings.
We observed a younger age at diagnosis in those with an
affected father or mother than in those with an affected sibling.
However, no difference was observed in age at diagnosis be-
tween children with familial and sporadic disease, similar to
most previous studies [4, 9, 25, 29]. As found in a Swedish
register-based study, index individuals with an affected sibling
were older than those in other familial groups and those with
sporadic disease [9]. In the current study, the transmission of
type 1 diabetes from an affected mother to a daughter was
more frequent than to a son, whereas almost the same frequen-
cy of boys and girls had an affected father or a sibling. In
addition, a clear majority of those with two or more affected
FDRs were boys. This was not, however, statistically signifi-
cant because of the small number of children in this group. In
contrast to our findings, it has been speculated that the disease
transmission rate is higher in offspring of the opposite sex to
that of the diabetic parent [2, 5]. Most previous studies have
not, however, supported this hypothesis, showing no differ-
ences [1, 4, 9, 29]. The DiMe study reported that if the affected
parent and the offspring shared the same sex then the risk of
developing type 1 diabetes was higher in sons compared with
daughters; when the parent and the offspring were of the
opposite sex, the risk was higher in daughters [2].
Accordingly, disease transmission was higher from an affect-
ed father than from an affected mother. In another study, fa-
thers were more likely to pass the disease to their daughters
than to their sons, but a similar effect was not seen for mothers
[5].
As previously shown, those without type 1 diabetes in the
immediate family had more severe metabolic decompensation
at diagnosis than those with familial disease [4, 8, 10–13]. The
observation of a lack of differences in metabolic control be-
tween those with familial and sporadic disease 1 year after
diagnosis [10] suggests that increased parental awareness of
diabetes-related symptoms and/or the possibility of self-
monitoring blood glucose without any delay in the families
with a previously affected family member, rather than differ-
ences in the disease pathogenesis, explain this phenomenon.
A higher frequency of ketoacidosis and increased weight loss
at diagnosis was observed in index children with an affected
father vs an affected mother. The results lend support to our
hypothesis that paternal type 1 diabetes is associated with
more severe disease in the offspring than maternal type 1
diabetes. To our knowledge, this is the first observation of
an association between paternal type 1 diabetes and a poorer
metabolic status in the offspring at diagnosis.
Since the FPDR does not collect data on the social status of
families, it was not possible to look for associations between
the familial environment and lifestyle and the disease presen-
tation in the index child. Whether the child is living with both
parents or with a single parent, often the mother, may affect
the recognition of diabetes-related symptoms prior to diagno-
sis. It is possible that mothers are still the primary caregivers,
responsible for children’s health issues and providing infor-
mation to clinicians. Whether this could have an effect on the
reported findings, for example the longer duration of classic
symptoms seen in those with an affected father compared with
the other familial subgroups, remains open.
The frequency of no detectable autoantibodies at diagnosis
was higher in children with familial vs sporadic disease, and
especially in those with multiple affected FDRs. This raises
the possibility of monogenic diabetes in some children with
affected family members. This issue is currently being
analysed in the FPDR population. The IAA frequency was
significantly higher in children with familial vs sporadic dis-
ease, while no differences were observed in other autoanti-
body titres or frequencies, or in the number of positive auto-
antibodies. Lebenthal et al reported similar results for IAA in
their study [12]. In addition, they found that individuals with
familial disease tested positive for three autoantibodies more
often than those with sporadic disease. However, most studies
have not found an association between a positive family his-
tory of type 1 diabetes and the presence of diabetes-related
autoantibodies [4, 8, 30]. Although our results from the auto-
antibody analyses do not support the theory of a more
0
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Fig. 3 Frequency of diabetic ketoacidosis (95%CI) at diagnosis of type 1
diabetes in children with different family members with diabetes and
children with sporadic type 1 diabetes. *p<0.05, **p<0.01,
***p<0.001 (adjusted for sex and age at diagnosis). Significance was
evaluated using logistic regression analysis
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Table 5 Demographic, metabolic, immunological and genetic markers in childrenwith parents diagnosed with type 1 diabetes before and after the birth
of the index child
Variable n Before, n=349 (87.0%) After, n=52 (13.0%) p value Adjusted p valuea
Demographics
Age at diagnosis, years, median (range) 401 6.98 (0.59–14.96) 9.57 (1.60–14.94) 0.001
Sex, male, % (95% CI) 401 54.4 (49.2, 59.7) 65.4 (52.5, 78.3) 0.183
Affected parent, father, % (95% CI) 401 66.2 (61.2, 71.2) 50.0 (36.4, 63.6) 0.034 0.006
Pubertal, % (95% CI) 313 12.1 (8.3, 15.9) 31.3 (15.2, 47.3) 0.007 0.964
Metabolic decompensation at diagnosis
Duration of symptoms, % 368 0.962 0.807
No symptoms 1.3 0
<1 week 37.3 36.7
1–4 weeks 47.6 51.0
>4 weeks 13.8 12.2
Impaired consciousness, % (95% CI) 386 1.8 (0.4, 3.2) 0 1.000 0.998
Ketoacidosis, % (95% CI) 393 7.9 (5.1, 10.8) 5.8 (0, 12.1) 0.782 0.645
Weight loss, kg, median (range) 368 0.30 (0–15.0) 1.10 (0–7.0) 0.065 0.442
Weight loss, %, median (range) 367 1.6 (0–21.3) 3.8 (0–19.7) 0.195 0.316
pH, median (range) 393 7.40 (6.97–7.54) 7.40 (7.20–7.45) 0.303 0.269
β-Hydroxybutyrate, mmol/l, median (range) 346 0.50 (0–12.1) 0.49 (0–17.4) 0.960 0.850
Plasma glucose, mmol/l, median (range) 396 21.7 (3.6–62.8) 20.3 (4.8–63.7) 0.417 0.452
HbA1c, mmol/mol, median (range) 63 72.0 (38.0–141.5) 107.0 (71.0–132.8) 0.007 0.007
HbA1c, %, median (range) 63 8.7 (5.6–15.1) 12.0 (8.7–14.3) 0.006 0.007
Autoantibodies
ICA, % (95% CI) 379 90.3 (87.1, 93.5) 92.0 (84.5, 99.5) 1.000 0.380
ICA, JDFU, median (range) 343 49.0 (3.0–2620.0) 64.0 (4.0–2048.0) 0.463 0.963
IAA, % (95% CI) 379 52.0 (46.6, 57.4) 32.0 (19.1, 44.9) 0.013 0.163
IAA, RU, median (range) 187 10.6 (2.9–484.9) 14.0 (3.0–338.7) 0.197 0.463
IA-2A, % (95% CI) 379 74.5 (69.8, 79.2) 88.0 (79.0, 97.0) 0.055 0.022
IA-2A, RU, median (range) 289 104.4 (0.9–202.5) 87.1 (1.4–157.5) 0.201 0.375
GADA, % (95% CI) 379 67.5 (62.4, 72.5) 62.0 (48.5, 75.5) 0.545 0.381
GADA, RU, median (range) 253 45.4 (5.4–3800.0) 47.9 (6.3–277.4) 0.782 0.385
ZnT8A, % (95% CI) 379 62.6 (57.4, 67.8) 76.0 (64.2, 87.8) 0.092 0.115
ZnT8A, RU, median (range) 244 10.4 (0.5–186.7) 17.0 (0.6–138.4) 0.396 0.297
Number of positive antibodies, median (mean) 379 4 (3.47) 4 (3.50) 0.701 0.292
Number of positive biochemical antibodies, median (mean) 379 3 (2.57) 3 (2.58) 0.810 0.932
Autoantibody negative, % (95% CI) 379 3.0 (1.2, 4.9) 6.0 (0, 12.6) 0.393 0.709
Positivity for multiple (≥2) autoantibodies, % (95% CI) 379 92.7 (89.9, 95.5) 94.0 (87.4, 1) 1.000 0.373
Genetics 401
DR3-DQ2/DR4-DQ8, % (95% CI) 22.9 (18.5, 27.3) 19.2 (8.5, 29.9) 0.677 0.483
DR3-DQ2/xb, % (95% CI) 14.0 (10.4, 17.7) 9.6 (1.6, 17.6) 0.513 0.465
DR4-DQ8/yc, % (95% CI) 53.6 (48.3, 58.8) 51.9 (38.3, 65.5) 0.940 0.923
xb/yc, % (95% CI) 9.5 (6.4, 12.5) 19.2 (8.5, 29.9) 0.059 0.069
DR3-DQ2, % (95% CI) 37.0 (31.9, 42.0) 28.8 (16.5, 41.2) 0.325 0.261
DR4-DQ8, % (95% CI) 76.5 (72.1, 81.0) 71.2 (58.8, 83.5) 0.505 0.424
Risk group, % 0.125 0.404
0 0.6 0
1 1.1 3.8
2 11.5 23.1
3 22.3 15.4
4 41.5 38.5
5 22.9 19.2
Categorical variables are presented as % (95% CI) and continuous variables as median (range)
For comparing frequencies, cross tabulation and χ2 -statistics with continuity correction or Fisher’s exact test when appropriate were used. Differences in
levels were determined using Kruskal–Wallis test or the Mann–Whitney U test. Adjustment for confounding factors was performed using logistic/
ordinal/multinomial regression for dichotomous/ordinal/categorical variables and quantile regression in R for skewed variables
a Adjusted for sex and age at diagnosis
b x ≠ DR4-DQ8
c y ≠ DR3-DQ2
JDFU, Juvenile Diabetes Foundation unit; RU, relative units
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aggressive, organ-specific immune response in index children
with an affected father, previous studies in at-risk individuals
have pointed in that direction. Verge et al reported that the
offspring of a father with type 1 diabetes were more likely to
seroconvert to positivity for diabetes-related autoantibodies
than the offspring of an affected mother [31]. Similarly, the
risk of developing multiple islet autoantibody positivity
tended to be higher in the offspring of affected fathers vs
affected mothers in the BABYDIAB study [32]. Moreover,
in that study the risk of multiple autoantibodies, as well as
the risk of developing type 1 diabetes, was strongly associated
with the presence of multiple FDRs with type 1 diabetes. This
is, in a way, in contrast to our finding of a higher frequency of
no detectable autoantibodies described above. However, as
the FPDR does not include any samples from the period be-
fore the diabetes diagnosis, we cannot exclude the possibility
that childrenwith familial disease had autoantibodies earlier in
the disease process but were already antibody negative at di-
agnosis due to aggressive beta cell loss. In the recent
Environmental Determinants of Diabetes in the Young study,
the risk of progression from multiple autoantibodies to type 1
diabetes was not related to the presence of an FDRwith type 1
diabetes compared with the general population series after
8 years of follow-up, but the progression rate was more rapid
in individuals with familial disease. In that study the relation-
ship of the affected relative to the index child did not affect
seroconversion or progression rates [33].
As previously reported from the FPDR, children with
familial type 1 diabetes carried the DR4-DQ8 risk haplo-
type more often than children with sporadic disease [4],
especially those with an affected father. Such a difference
was not seen in the prevalence of the DR3-DQ2 risk hap-
lotype. On the contrary, the proportion of genotypes not
including DR3-DQ2 and/or DR4-DQ8 was significantly
reduced among children with familial disease, as described
previously by Veijola et al [8]. In their data, the highest
frequency of the DR3/DR4 genotype was seen in children
with an affected sibling, while the DR4/x genotype was
most common in children with an affected parent.
Although these findings were non-significant, the current
results are in line with those observations. Vadheim et al
found that fathers with the DR4 allele transmit this allele
more often to their offspring than DR4-positive mothers,
suggesting that a preferential inheritance of the DR4 allele
in children of affected fathers could explain the increased
incidence of type 1 diabetes in the offspring of an affected
father [14]. Similarly, high-risk HLA haplotypes were more
likely to be transmitted to the offspring from a father than a
mother with type 1 diabetes in a study by Tuomilehto-Wolf
et al [15]. Although the findings potentially indicate that
the affected father is characterised by an increased suscep-
tibility for transferring certain high-risk haplotypes to their
offspring, interpretations should be made with caution,
since studies comparing the association between different
affected family members and the HLA genotype in the in-
dex individual are sparse and the study populations in pre-
vious studies have usually been small.
When comparing index children with an affected parent
diagnosed before vs after the birth of that child, we found no
differences in the sex distribution of the offspring. In contrast,
a higher male:female ratio among the affected parents was
observed, but only if the parent was diagnosed before the birth
of the index child. Similar results have been reported by
Lorenzen et al, although their subpopulation was relatively
small [29]. These findings support the hypothesis, first pro-
posed by Warram et al [1], of a protective effect of maternal
insulin treatment during pregnancy by inducing tolerogenic
mechanisms to insulin. Exogenous insulin is transferred ex-
tensively to the fetus through the antigen–antibody complexes
present in most insulin-treated mothers [34]. Similar differ-
ences have not been observed, however, in all studies [35].
In the BABYDIAB study, children with a father affected by
type 1 diabetes developed positive autoantibodies earlier and
at a higher frequency than children with an affected mother
[36]. Thus, male sex of the affected parent seems to more
strongly influence the initiation of autoimmunity to diabetes-
associated autoantigens than disease progression. The longer
history and experience of type 1 diabetes in affected parents
diagnosed before the birth of the index child may explain the
lower HbA1c values in these index children at diagnosis, com-
pared with those whose parents were diagnosed after their
birth. However, similar differences were not seen in other
metabolic values, probably because of limited statistical
power.
The large study population of almost 5000 newly diag-
nosed children, derived from a nationwide register in the
country with the highest incidence of type 1 diabetes, is a clear
strength of our study. However, the retrospective design can
be considered a limitation. Information on the presence of a
family history of diabetes in relatives and the type of diabetes
(type 1/type 2/gestational diabetes/other) was collected direct-
ly from the participating families using a questionnaire, which
may possibly have led to some misclassifications. However,
the risk of bias as to the family history of FDRsmay have been
smaller than if the extended family had also been included.
Another source of selection bias is the inclusion criterion re-
quiring sample availability for autoantibody and HLA analy-
ses, although the frequency of children with familial and spo-
radic disease did not differ between those included and ex-
cluded [20].
In conclusion, the higher frequency of ketoacidosis and
greater weight loss at diagnosis in the offspring of an affected
father, in addition to fathers’ susceptibility to transferring the
disease to their offspring more often than mothers, suggest
that paternal type 1 diabetes seems to be associated with more
severe disease in the offspring. This suggests that the children
2038 Diabetologia (2019) 62:2025–2039
of fathers with type 1 diabetes might have a higher risk of
diabetic complications than those of affected mothers.
However, no studies to date have addressed that issue. No
differences were observed in the autoantibody profile at diag-
nosis. The DR4-DQ8 haplotype was more frequent in children
with familial compared with sporadic disease, and especially
among those with a father affected by type 1 diabetes. Both
genetic and environmental factors have been implicated to
explain the higher incidence of type 1 diabetes in childrenwith
an affected father than in those with an affected mother. The
sex difference seen between affected parents diagnosed before
and after the birth of the index child supports the hypothesis
that maternal type 1 diabetes protects against the development
of type 1 diabetes in children.
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